BIOVIE INC. BIVI
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-45.44
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$17.5M | — | — | $19.0M |
| 2024 | — | -$32.1M | — | — | $15.5M |
| 2023 | — | -$50.3M | — | — | $15.3M |
| 2022 | — | -$26.1M | — | — | $3.7M |
| 2021 | — | -$130.2M | — | — | $5.1M |
| 2020 | — | -$16.7M | — | — | -$21.5M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| DO CUONG V | President & CEO | 2025-08-07 | Buy | 5,000 | — |
| ROGICH SIGMUND | director | 2024-11-20 | Grant | 32,700 | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -45.44 (distress)
- Working capital / assets 0.854
- Retained earnings / assets -16.332
- EBIT / assets -0.838
- Equity / liabilities 7.455
Source: SEC EDGAR filings · CIK 0001580149 · as of 2025-06-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.